Zenith Technologies appoints serialization director
![](/46/pdcnewsitem/04/15/80/Carlos%20Machado.jpg)
Carlos Machado, appointed as serialization director, Zenith Technologies.
The appointment comes as the pharmaceutical industry faces the challenge of complying with new legal requirements for the authentication and barcoding of licensed drug products.
A global life science technology firm, with headquarters in Ireland, has appointed Carlos Machado as serialization director to lead the company’s sales, operations, implementation and post project support services in the US.
The appointment comes as the pharmaceutical industry faces the challenge of complying with new legal requirements for the authentication and barcoding of licensed drug products from November 2017 in the US and early 2019 in Europe.
Carlos joins Zenith Technologies with significant experience of assisting pharmaceutical manufacturers with track and trace technologies, having worked on more than 75 serialization projects from both an operations and delivery perspective.
In his former role as director of global operations at a leading anti-counterfeiting technology provider, Carlos helped to pioneer the serialization concept and define the future of authentication.
Jim Lehane, director at Zenith Technologies, said: “Serialization is a real challenge for our customers and it’s an important time for us to add further expertise to our team. Carlos’ background in track and trace technologies and his knowledge of the implementation challenges pharmaceutical manufacturers face, make him ideally suited to lead our serialization offering in the US, helping our customers achieve seamless compliance with the new regulations.
“Zenith Technologies has strong partnerships with many of the world’s largest pharmaceutical manufacturers as well as life science companies of all sizes, providing automation consulting and local support services. Carlos’ appointment will help us to take our US offering to the next level.”
Commenting on his appointment, Carlos said: “Serialization is a huge priority for Zenith Technologies as we understand the challenges customers face in addressing supply chain security and preventing the introduction and distribution of counterfeit product into the global marketplace. It is an exciting time to join the firm as we expand our US presence, leveraging our technological experience, sound project management practices, skilled engineers and world-class implementation and support services.
“When it comes to complying with new serialization regulations, the industry, ranging from the top pharmaceutical companies to contract manufacturing organizations (CMOs), understands what needs to be done. The challenge lies in the scale and complexity of the task ahead. In my new position, it is my responsibility to draw on my industry experience and work alongside our customers to simplify the implementation process and provide flawless execution.”
The announcement is the next stage in Zenith Technologies’ goal to assist companies in the US and Europe with the challenge of serialization. The company recently announced a global partnership with software provider SEA Vision to support pharmaceutical companies with the installation and integration of serialization solutions across drug manufacturing sites.
Carlos continued: “Given our combined expertise and remarkable track record, it’s a natural marriage. We will be working exclusively with SEA Vision to improve existing processes and delivery time, implement its technology and systems and enhance the overall customer experience.
“Our organizations are also working towards providing an innovative interactive e-learning environment to assist our customers with serialization training. We are also actively recruiting and adding experienced talent to our serialization taskforce in the US to ensure we can continue to deliver a high level of service at a local level.”
Marco Baietti, commercial director at SEA Vision said: “Carlos provides a unique combination of leadership skills and expertise in the serialization field thanks to his specialist background. We are thrilled to welcome him to the team and look forward to working together to deliver our shared goal to provide the best track & trace solutions and services in the markets that we serve.
Related News
-
News Ophthalmologic drug product Eylea faces biosimilar threats after FDA approvals
Regeneron Pharmaceutical’s blockbuster ophthalmology drug Eylea is facing biosimilar competition as the US FDA approves Biocon’s Yesafili and Samsung Bioepis/Biogen’s Opuviz. -
News ONO Pharmaceutical expands oncology portfolio with acquisition of Deciphera
ONO Pharmaceutical, out of Japan, is in the process of acquiring cancer-therapy maker Deciphera Pharmaceuticals for US$2.4 billion. -
News First offers for pharma from Medicare drug price negotiations
Ten high-cost drugs from various pharma manufacturers are in pricing negotiations in a first-ever for the US Medicare program. President Biden’s administration stated they have responded to the first round of offers. -
News Eli Lilly’s Zepbound makes leaps and bounds in weight-loss drug market
In the last week, Eli Lilly has announced their partnership with Amazon.com’s pharmacy unit to deliver prescriptions of Zepbound. Zepbound has also surpassed Novo Nordisk’s Wegovy for the number of prescriptions for the week of March 8.&nbs... -
News Chasing new frontiers at LEAP – The National Biotechnology Strategy Keynote
On the third day of LEAP (4–7 March 2024, Riyadh Exhibition and Convention Centre, Malham, Saudi Arabia) the CPHI Middle East team hosted the Future Pharma Forum, to set the scene for an exciting new event for the pharma community, coming to Riya... -
News Pfizer maps out plans for developing new oncology therapeutics by 2030
Pfizer dilvulges plans to investors around growing their cancer portfolio, and the drugs they will be focusing on developing after their aquisition of Seagen in 2023. -
News Generics threat to Merck’s Bridion as Hikma seeks pre-patent expiry approval
Merck has disclosed they received notice from Hikma Pharmaceuticals for seeking a pre-patent expiry US FDA approval for Hikma’s generic version of Merck’s Bridion. -
News Bernie Sanders vs Big Pharma - the latest on drug price negotiations
In a hearing in front of the US Senate, three of the biggest pharmaceutical companies in America are challenged over exorbitant prescription drug prices, with Sanders claiming their actions are limiting the population's access to affordable healthc...
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance